The Changing Landscape in Pancreatic Ductal Adenocarcinoma Management: From Tumor Biology to Clinical Practice

Dear Colleagues, 

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer with little improvement in the survival rates over the past few decades. It is the fourth leading cause of cancer-related mortality in the USA and in Europe. The prognosis of patients with this disease remains unfavorable for all stages of disease, with the 5-year overall survival rate being <5%. Surgical resection, followed by adjuvant therapy, is the only radical therapeutic option; however, <15% of patients present with operable disease. Patients with advanced disease at presentation or recurrence may receive palliative chemotherapy, although the rates of response and survival benefit are modest. Aggressive tumor biology as well as primary or secondary drug resistance contribute significantly toward this dismal prognosis.

In this context, the aim of the current Special Issue is to bring to the scientific community’s attention new research and findings in the field of pancreatic cancer biology and therapeutic advances. It is the hope of the guest editors that this collection will result in new insights into this deleterious type of cancer and provide new information regarding the so many still unmet needs in the field.

The guest editors welcome all kinds of papers that could help the scientific community to advance in the field: original articles, reviews, case reports, and short reports of important findings are welcome.

We cordially invite researchers working in the field to contribute original research articles as well as critical review articles, case reports, and short reports of important findings that can shed more light in the fight against pancreatic cancer.

Dr. Konstantinos Dimas
Dr. Konstantinos Kamposioras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.